COMMANDS Trial HRQoL Results Unveiled at ASH 2024: Esther Oliva Reports

Esther Oliva, MD, of Massachusetts General Hospital and Harvard Medical School dives into the health-related quality of life analysis from the phase 3 COMMANDS trial, a study evaluating treatment outcomes of luspatercept treatment  for patients with myelodysplastic syndromes. Presented at the 66th American Society of Hematology annual Meeting & Exposition, these results highlight how innovative therapies are impacting the lives of patients beyond clinical efficacy. Esther explains the study’s methodology, key findings, and their implications for patient care.